Results 51 to 60 of about 3,957 (191)

79O Clinical performance of Immunoscore® in early colon cancer in the Asian population

, 2020
Background Immunoscore® is an in vitro diagnostic test predicting the risk of relapse in early-stage Colon Cancer (CC), by measuring the host immune response at the tumor site.
Kawakami, Y., Ascierto, P.A., Fox, B.A., Ohashi, P.S., ESMO World Congress on Gastrointestinal Cancer - GASTROINTESTINAL TUMOURS, COLORECTAL, Vora, H., Nagtegaal, I.D., Zavadova, E., Galon, J., Roehrl, M.H.A., Patel, P.S., Marincola, F., Marliot, F., Hartmann, A., Van den Eynde, Marc, Wang, Y., Torigoe, T., Pagès, F., Mlecnik, B., Bifulco, C.B., Lugli, A.   +20 more
core   +1 more source

Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma [PDF]

Frontiers in Oncology, 2019
Objective: This study evaluated the prognostic value of the newly-built Immunoscore (neo-Immunoscore) in patients with renal cell carcinoma (RCC). Methods: Eighty-two patients with RCC were enrolled in this study. Their 3- and 5-year survival rates and overall survival (OS) were evaluated.
Congfang Guo, Congfang Guo, Congfang Guo, Congfang Guo, Congfang Guo, Congfang Guo, Hua Zhao, Hua Zhao, Hua Zhao, Hua Zhao, Hua Zhao, Yu Wang, Shuai Bai, Zizhong Yang, Feng Wei, Feng Wei, Feng Wei, Feng Wei, Feng Wei, Xiubao Ren, Xiubao Ren, Xiubao Ren, Xiubao Ren, Xiubao Ren   +23 more
openaire   +3 more sources

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

OncoImmunology, 2020
The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers.
Anastasia Lanzi, F. A. Sinicrope, A. B. Benson, Jérôme Galon   +3 more
doaj   +1 more source

Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma

Current Oncology, 2021
This study aimed to elucidate the prognostic implications of intratumoral and peritumoral infiltrating T-lymphocytes in pancreatic ductal adenocarcinoma (PDAC) through a meta-analysis.
Jung-Soo Pyo, Byoung Kwan Son, Hyo Young Lee, Il Hwan Oh, Kwang Hyun Chung   +4 more
doaj   +1 more source

A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma

Cancer Biology & Medicine, 2021
Objective: The immunoscore, which is used to quantify immune infiltrates, has greater relative prognostic value than tumor, node, and metastasis (TNM) stage and might serve as a new system for classification of colorectal cancer.
Qiujuan Huang, Tongyuan Qu, Lisha Qi, Changxu Liu, Yuhong Guo, Qianru Guo, Guangning Li, Yalei Wang, Wenshuai Zhang, Wei Zhao, Danyang Ren, Leina Sun, Shengguang Wang, Bin Meng, Baocun Sun, Bin Zhang, Wenjuan Ma, Wenfeng Cao   +17 more
doaj   +1 more source

Integration of an OS-Based Machine Learning Score (AS Score) and Immunoscore as Ancillary Tools for Predicting Immunotherapy Response in Sarcomas. [PDF]

Cancers (Basel)
Angiosarcomas (ASs) are a highly aggressive subset of sarcomas. This study aimed to develop and validate an immune-related prognostic model, termed the AS score, using two independent sarcoma cohorts.
Machado I, López-Reig R, Giner E, Fernández-Serra A, Requena C, Llombart B, Giner F, Cruz J, Traves V, Lavernia J, Llombart-Bosch A, López Guerrero JA.   +11 more
europepmc   +2 more sources

O16 Immunoscore® Colon analytical performance

, 2016
Background The Immunoscore® was validated as a powerful prognostic marker in colon cancer in a study conducted by the Immunoscore® worldwide consortium, led by the Society for Immunotherapy of Cancer (SITC) involving 23 pathology centers from 17 ...
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), Van den Eynde, Marc   +1 more
core   +1 more source

Advancements and prospects in bioinformatics and omics for colorectal cancer: A dual bibliometric analysis of global trends and top cited publications

Journal of Intelligent Medicine, EarlyView.
This dual bibliometric analysis examined 5129 publications and the top 100 most cited publications on bioinformatics and omics in colorectal cancer (2004–2025) from the Web of Science Core Collection. Using SCImago Graphica, VOSviewer, CiteSpace, and R Studio, we analyzed global trends, countries/regions, institutions, journals, authors, references ...
Yue Huang, Ziye Peng, Xiangyu Wang, Likun Yang, Yifei Gao, Ximo Wang, Jiaxin Li, Zhengcun Pei   +7 more
wiley   +1 more source

Immunoscore: redefining the landscape of colorectal cancer control and care. [PDF]

Future Oncol
The Immunoscore (IS), introduced by Jerome Galon in the early 2000s, evaluates immune cell densities within tumors, offering a more accurate prediction of clinical outcomes in colorectal cancer (CRC) compared to the TNM system. Studies have demonstrated that IS enhances the prediction of recurrence, disease-free survival, and overall survival in early ...
Zakhour J, Njeim M, Haddad R, Akiki J, Njeim C, Nakouzi N, Rustom M, Karam E, Kesrouani C, Gharios J, Kourie HR.   +10 more
europepmc   +3 more sources

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

, 2019
Introduction: Immunoscore® is an in vitro diagnostic test that predicts the risk of relapse in patients with early-stage Colon Cancer (CC) by measuring the host immune response at the tumor site. It is a risk-assessment tool that provides independent and
Fox, B., Fox, Bernard A, Hermitte, F, Nagtegaal, I., Hartmann, A, Roehrl, M, Ohashi, P, Roehrl, M., Zavadova, E., Torigoe, T, Galon, J., Kawakami, Y, Marincola, F., Mlecnik, B, Marliot, F, Marliot, F., Patel, P., Hermitte, F., Torigoe, T., Mlecnik, B., Lugli, A., Kawakami, Y., Marincola, F, Wang, Y, Bifulco, C., Lugli, A, Pagès, F, Ascierto, P, Galon, J, ESMO Congress 2019, Nagtegaal, I, Zavadova, E, Ohashi, P., Bifulco, Carlo, Hartmann, A., Van den Eynde, Marc, Van den Eynde, M, Wang, Y., Ascierto, P., Pagès, F., Patel, P   +40 more
core   +1 more source